Impact of Brokerage Rating on Regeneron Pharmaceuticals, Inc.(REGN)

Many Regeneron Pharmaceuticals, Inc.(REGN) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Regeneron Pharmaceuticals Inc was Reiterated by RBC Capital Mkts on Jan 6, 2017 to Outperform, Lowers Price Target to $ 598 from a previous price target of $626 .Regeneron Pharmaceuticals Inc was Reiterated by Chardan Capital Markets on Jan 6, 2017 to Neutral, Lowers Price Target to $ 345 from a previous price target of $350 .Regeneron Pharmaceuticals Inc was Upgraded by Credit Suisse to Outperform on Dec 20, 2016. Company shares were Upgraded by Chardan Capital Markets on Dec 12, 2016 to Neutral, Raises Price Target to $ 350 from a previous price target of $300 .

Company has reported several Insider transactions to the SEC, on Dec 14, 2016, Charles A Baker (director) sold 3,000 shares at 392.48 per share price.On Nov 16, 2016, Arthur F Ryan (director) sold 2,000 shares at 429.34 per share price.On Nov 15, 2016, Joseph L Goldstein (director) sold 2,125 shares at 450.00 per share price.

Regeneron Pharmaceuticals Inc Last issued its quarterly earnings results on Feb 9, 2017. The company reported $3.04 EPS for the quarter, missing the analyst consensus estimate by $ -0.04. Analyst had a consensus of $3.08. The company had revenue of $1227.00 million for the quarter, compared to analysts expectations of $1302.26 million. The companys revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.83 EPS.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received a short term rating of strong sell from experts at Zacks with a rank of 5. The stock has been rated an average of 2.22 by 18 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 2 stock experts have also suggested a buy rating. 10 Brokerage Firms have advised hold.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): 15 analysts have set the short term price target of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at $424.73. The standard deviation of short term price target has been estimated at $64.68, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 598 and $345 respectively.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rose 0.23% or 0.86 points on Tuesday and made its way into the gainers of the day. After trading began at $375.95 the stock was seen hitting $378.32 as a peak level and $371.605 as the lowest level. The stock ended up at $376.52. The daily volume was measured at 991,873 shares. The 52-week high of the share price is $452.96 and the 52-week low is $325.35. The company has a market cap of $39,942 million.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regenerons platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)


Share this post

Post Comment